ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Celltrion, Inc.

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

 

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

 

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

 

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2020 KRWUSD
Revenue1,849.11B1,567.19M
Gross Profit1,010.17B856.15M
Operating income712,108.52M603.53M
Income before tax648,091.46M549.28M
Net income511,289.00M433.33M
EBITDA891,418.16M755.51M
Diluted EPS3,729.853.16
Dividends Per Share00
Total Assets5,047.69B4,646.68M
Total liabilities1,592.54B1,466.02M
Total equity3,335.25B3,070.28M
Operating cash flow342,017.88M289.87M
Currency in KRWCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 670,580.96M 949,079.96M 982,074.95M 1,128.45B 1,849.11B
Gross Profit 388,407.95M 685,318.99M 541,284.44M 623,222.91M 1,010.17B
Operating income 249,614.31M 507,771.41M 338,291.33M 378,062.36M 712,108.52M
Income before tax 228,752.75M 491,503.19M 317,725.82M 374,013.70M 648,091.46M
Net income 177,994.50M 382,467.03M 261,841.76M 297,556.85M 511,289.00M
EBITDA 338,289.64M 605,721.68M 465,057.52M 537,282.22M 891,418.16M
Diluted EPS 1,304.89 2,739.78 1,905.45 2,175.18 3,729.85
Dividends Per Share 0 0 0 0 0
Total Assets 3,117.56B 3,410.79B 3,628.33B 3,893.69B 5,047.69B
Total liabilities 914,607.61M 975,863.55M 992,561.59M 986,733.41M 1,592.54B
Total equity 2,053.63B 2,308.89B 2,524.02B 2,794.15B 3,335.25B
Operating cash flow 230,062.47M 482,870.20M 372,074.18M 468,031.66M 342,017.88M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 577.99M 839.51M 892.37M 967.65M 1,567.19M
Gross Profit 334.77M 606.20M 491.84M 534.41M 856.15M
Operating income 215.14M 449.15M 307.39M 324.18M 603.53M
Income before tax 197.16M 434.76M 288.70M 320.71M 549.28M
Net income 153.41M 338.31M 237.92M 255.15M 433.33M
EBITDA 291.58M 535.79M 422.58M 460.71M 755.51M
Diluted EPS 1.12 2.42 1.73 1.86 3.16
Dividends Per Share 0 0 0 0 0
Total Assets 2,581.19M 3,186.01M 3,251.78M 3,366.93M 4,646.68M
Total liabilities 757.25M 911.55M 889.55M 853.24M 1,466.02M
Total equity 1,700.31M 2,156.73M 2,262.07M 2,416.14M 3,070.28M
Operating cash flow 198.29M 427.12M 338.09M 401.33M 289.87M

Valuation Measures

Dec 2020
PER95.73
ROA11.43%
ROE16.68%
Operating margin38.51%
Profit margin27.65%

Key executives

  • Chief Executive Officer & Director: Wu-Sung Ki
  • Finance Director: Ho-Seop Lee
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Sang-Joon Lee
  • Vice President: Jung-Won Yoon

Shareholders

  • SEO JUNG-JIN (22.1%)
  • National Pension Service of Korea (7.9%)
  • Temasek Holdings Pte Ltd. (Investment Management) (7.4%)
  • The Vanguard Group, Inc. (1.8%)
  • BlackRock Fund Advisors (1.6%)
  • Celltrion, Inc. (0.8%)
  • Norges Bank Investment Management (0.8%)
  • Mirae Asset Global Investments Co., Ltd. (0.5%)
  • Samsung Asset Management Co., Ltd. (0.5%)
  • BlackRock Advisors (UK) Ltd. (0.5%)

Contact Details

Related Companies

  • Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
  • Celltrion Inc. Employee Stock Ownership ASSN.
  • Celltrion Pharm Inc.

Competitors

  • Novartis AG
  • Pfizer Inc.
  • AbbVie, Inc.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Biocon Limited
  • Viatris, Inc.
  • Merck KGaA
  • SAMSUNG BIOLOGICS Co., Ltd.
  • EPIRUS Biopharmaceuticals, Inc.
  • Reyon Pharmaceutical Co., Ltd.
  • Binex Co., Ltd
  • PharmGen Science, Inc.
  • Sinocelltech Group Limited Class A
  • Mabion SA
  • Green Cross Corporation
  • Bukwang Pharmaceutical Co., Ltd.
  • ALTEOGEN Inc.
  • PharmAbcine Inc.
  • SK Chemicals Co., Ltd.
Last Updated on 12 May, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more